Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib plus EGFR TKI in non-T790M resistant NSCLC
NCT03766490Unknown
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03766490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03766490.